| Trial # | Type | Study Status | Status Date | Title |
|---|
| Alliance A071701 | Brain Advanced | Open Active | 2020-05-21 | Alliance A071701: Genomically-Guided Treatment Trial in Brain Metastases |
| Alliance A011401 | Breast Adjuvant | Open Active | 2016-09-17 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2019-01-15 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2020-03-27 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2019-06-24 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| Alliance Foundation Trials AFT-25 | Breast Other | Open Active | 2019-04-05 | Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial |
| Alliance A021502 | GI Colorectal Adjuvant | Open Active | 2018-10-12 | Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair |
| SWOG S0820 | GI Colorectal Prevention | Open Active | 2018-07-27 | SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) |
| ECOG-ACRIN EA2165 | GI Other | Open Active | 2019-04-15 | ECOG-ACRIN EA2165: A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer |
| SWOG S1815 | GI Other | Open Active | 2020-06-22 | SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers |
| INST 96144 | Ill Defined | Open Active | 2015-07-28 | INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives |
| SWOG S1609 | Ill Defined | Open Active | 2019-12-10 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-12 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2019-03-01 | ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-04-09 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2020-01-03 | ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2019-08-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1C | Solid Tumors Other | Open Active | 2020-05-07 | ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2019-11-15 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2019-09-16 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1K | Solid Tumors Other | Open Active | 2019-07-29 | ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations |
| DCP-001 | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| DCP-001A | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001B | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001C | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001D | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| Alliance A011401 | Breast Adjuvant | Open Active | 2016-12-16 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2019-01-15 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2020-03-27 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| INST University of Arizona 1807 | Breast Advanced | Open Active | 2020-02-17 | INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer |
| NRG Oncology NRG-BR004 | Breast Advanced | Open Active | 2019-09-24 | NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-08-21 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| EA1181 | Breast Neoadjuvant | Open Active | 2020-05-14 | EA1181: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer) |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2020-11-05 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| Alliance Foundation Trials AFT-25 | Breast Other | Open Active | 2019-03-27 | Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial |
| SWOG S1703 | Breast Other | Open Active | 2020-04-28 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
| SWOG S1815 | GI Other | Open Active | 2020-06-22 | SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| Pharm 010-02 | GU Prostate Advanced | Open Active | 2020-03-04 | Merck 010-02: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) PlusOlaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010) |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2011-02-07 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2020-05-18 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
| SWOG S1609 | Ill Defined | Open Active | 2019-12-10 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| UNM 1709 | Ill Defined | Open Active | 2019-07-02 | INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER) |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2019-03-01 | ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-03-26 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2020-01-03 | ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2019-08-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1C | Solid Tumors Other | Open Active | 2020-05-07 | ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2019-11-15 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2019-09-16 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1K | Solid Tumors Other | Open Active | 2019-07-29 | ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations |
| DCP-001 | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| DCP-001A | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001B | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001C | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001D | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| ECOG-ACRIN E1Q11 | Supportive | Open Active | 2018-04-18 | ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2019-01-15 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2020-03-27 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| Alliance A221505 | Breast Advanced | Open Active | 2018-04-10 | Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| NRG Oncology NRG-BR004 | Breast Advanced | Open Active | 2019-12-18 | NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-11-05 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| SWOG S0820 | GI Colorectal Prevention | Open Active | 2018-09-14 | SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) |
| SWOG S1815 | GI Other | Open Active | 2020-06-22 | SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers |
| NRG Oncology NRG-HN004 | Head And Neck Advanced | Open Active | 2019-03-20 | NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin |
| NRG Oncology NRG-GU005 | GU Prostate Advanced | Open Active | 2018-01-29 | NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| Pharm PrTK03 | GU Prostate Adjuvant | Open Active | 2017-06-28 | Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer |
| SWOG S1609 | Ill Defined | Open Active | 2019-12-10 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| INST 96144 | Ill Defined | Open Active | 2014-12-09 | INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives |
| Pharm INCB 18424-MA-GD-301 | Hematology Stem Cell Transplant | Open Active | 2019-01-29 | Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant |
| RTOG 1216 | Head And Neck Advanced | Open Active | 2020-07-24 | RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck |
| SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-04-17 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2019-03-01 | ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-17 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| UNM 1709 | Ill Defined | Open Active | 2019-07-02 | INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER) |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2019-08-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| SWOG S1801 | Skin Melanoma Advanced | Open Active | 2020-05-06 | SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma |
| ECOG-ACRIN EA6141 | Skin Melanoma Advanced | Open Active | 2020-08-07 | ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2020-01-03 | ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2019-09-16 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2019-11-15 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1C | Solid Tumors Other | Open Active | 2020-05-07 | ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1K | Solid Tumors Other | Open Active | 2019-07-29 | ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| Alliance A071701 | Brain Advanced | Open Active | 2020-04-17 | Alliance A071701: Genomically-Guided Treatment Trial in Brain Metastases |
| Pharm LNS-101 | Advanced Solid Tumors | Open Active | 2019-10-11 | Linnaeus Therapeutics LNS-101: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer Including Immunotherapy Refractory Expansion Cohorts With and Without Pembrolizumab |
| Alliance A011401 | Breast Adjuvant | Open Active | 2016-10-02 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| Alliance A011202 | Breast Adjuvant | Open Active | 2020-05-27 | Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
| NRG Oncology NRG-BN003 | Brain Other | Open Active | 2017-10-20 | NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma |
| NCCTG N0577 | Brain Advanced | Open Active | 2017-12-18 | NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma |
| Alliance A071801 | Brain Advanced | Open Active | 2020-06-11 | Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-03-28 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| Alliance A221505 | Breast Advanced | Open Active | 2018-04-10 | Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2020-03-27 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2019-01-15 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| Pharm SGNLVA-002 | Breast Advanced | Open Active | 2018-02-20 | Seattle Genetics SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer |
| Novartis CBYL719X2402 | Breast Advanced | Open Active | 2020-05-19 | Novartis CBYL719X2402: A Phase II, Multicenter, Open-label, Two-cohort, Noncomparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients with PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), who have Progressed on or after CDK 4/6 Inhibitor Treatment |
| NRG Oncology NRG-BR004 | Breast Advanced | Open Active | 2019-09-24 | NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer |
| INST University of Arizona 1807 | Breast Advanced | Open Active | 2019-10-24 | INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer |
| ECOG-ACRIN EA1183 | Breast Advanced | Open Active | 2020-10-19 | ECOG-ACRIN EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2019-06-24 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| EA1181 | Breast Neoadjuvant | Open Active | 2020-05-14 | EA1181: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer) |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-09-05 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| SWOG S1501 | Breast Advanced | Open Active | 2020-11-20 | SWOG S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III |
| Alliance A231701CD | CCDR | Open Active | 2020-07-10 | Alliance A231701CD: Increasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision Making through a Shared Decision Making Intervention |
| SWOG S1703 | Breast Other | Open Active | 2020-03-02 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
| ECOG-ACRIN EA1151 | Breast Other | Open Active | 2018-08-31 | ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST) |
| Alliance Foundation Trials AFT-25 | Breast Other | Open Active | 2018-02-07 | Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial |
| UNM 1607 | Breast Neoadjuvant | Open Active | 2018-04-16 | INST UNM 1607: Monitoring response to neoadjuvant chemotherapy (NAC) in Early Stage Breast Cancer (ESBC) Using High-speed MR Spectroscopic Imaging (MRSI) |
| UNM TCCP | Epidemiological | Open Active | 2017-12-08 | INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer |
| UNM 1803 | Epidemiological | Open Active | 2018-06-26 | INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative |
| INST 1311 | Epidemiological | Open Active | 2017-06-20 | INST 1311: A Prospective Birth Cohort Study Involving Environmental Uranium Exposure in the Navajo Nation |
| CIBMTR Protocol for a Research Database | Epidemiological | Open Active | 2020-11-10 | CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries |
| SWOG S0820 | GI Colorectal Prevention | Open Active | 2017-10-05 | SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) |
| INST UNM 1809 | GI Colorectal Prevention | Open Active | 2018-12-27 | INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States |
| Alliance A021703 | GI Colorectal Advanced | Open Active | 2020-03-03 | Alliance A021703: Randomized Double-blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS) |
| Alliance A021502 | GI Colorectal Adjuvant | Open Active | 2018-10-12 | Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair |
| SWOG S1815 | GI Other | Open Active | 2020-06-22 | SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers |
| ECOG-ACRIN EA2165 | GI Other | Open Active | 2019-04-08 | ECOG-ACRIN EA2165: A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer |
| Alliance A021602 | GI Other | Open Active | 2019-05-08 | Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) |
| Pharm 937-00 | GI Hepatic Adjuvant | Open Active | 2020-02-04 | Merck 937-00: A Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) |
| PHARM CP-MGAH22-06 | GI Gastric Advanced | Open Active | 2020-03-13 | MacroGenics CP-MGAH22-06: A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-nave, HER2-Positive Gastric or Gastroesophageal Junction Cancer |
| Pharm FGCL-3019-087 | GI Pancreatic Advanced | Open Active | 2020-07-16 | FibroGen FGCL-3019-087: A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer |
| ECOG-ACRIN EA2186 | GI Pancreatic Advanced | Open Active | 2020-11-19 | ECOG-ACRIN EA2186: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Nave Metastatic Pancreatic Cancer (GIANT) |
| Alliance A021806 | GI Pancreatic Adjuvant | Open Active | 2020-12-08 | Alliance A021806: A Phase III Trial Of Perioperative Versus Adjuvant Chemotherapy For Resectable Pancreatic Cancer |
| UNM 1603 | GI Other | Open Active | 2016-11-30 | INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health |
| SWOG S1820 | GI Other | Open Active | 2020-08-05 | SWOG S1820: A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC) |
| Pharm PrTK03 | GU Prostate Adjuvant | Open Active | 2017-06-28 | Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer |
| UNM 1805 | GU Other | Open Active | 2019-01-08 | INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors |
| Pharm 905-00 | GU Other | Open Active | 2020-02-04 | Merck 905-00: A Phase 3 Randomized Study of Cystectomy plus Peri-operative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Patients with Muscle-invasive Bladder Cancer (KEYNOTE-905) |
| Pharm 866-00 | GU Other | Open Active | 2019-11-04 | Merck 866-00: A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866) |
| Alliance A031704 | GU Renal Cell Advanced | Open Active | 2019-11-26 | Alliance A031704: PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated REnal cell cancEr (PDIGREE) |
| Pharm 010-02 | GU Prostate Advanced | Open Active | 2020-02-10 | Merck 010-02: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) PlusOlaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010) |
| NRG Oncology NRG-GU005 | GU Prostate Advanced | Open Active | 2018-01-29 | NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| Pharm C-750-01/GOG-3028 | GYN Cervical Advanced | Open Active | 2019-11-14 | Agenus C-750-01/GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (antiPD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS |
| NRG Oncology NRG-GY006 | GYN Cervical Advanced | Open Active | 2020-02-18 | NRG Oncology NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer |
| RTOG 0724/GOG-0724 | GYN Cervical Adjuvant | Open Active | 2015-07-23 | RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2010-10-20 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| Pharm GU17-295 | GU Ureter Advanced | Open Active | 2020-11-11 | Hoosier HCRN GU17-295: A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma |
| NCICOVID | GYN Other | Open Active | 2020-07-14 | NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study |
| Pharm 4010-03-001 | GYN Endometrial Advanced | Open Active | 2020-11-02 | Tesaro 4010-03-001: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer |
| NRG-GY018 | GYN Endometrial Advanced | Open Active | 2020-12-10 | NRG Oncology NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer |
| VBL Therapeutics VB-111-701/GOG 3018 | GYN Ovarian Advanced | Open Active | 2019-08-29 | VBL Therapeutics VB-111-701/GOG 3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer |
| NRG-GY009 | GYN Ovarian Advanced | Open Active | 2020-09-14 | NRG Oncology NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer |
| GOG-3026 | GYN Ovarian Advanced | Open Active | 2020-03-27 | GOG-3026: A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum |
| UNM 1509 | GYN Other | Open Active | 2020-06-29 | INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies |
| RTOG 1216 | Head And Neck Advanced | Open Active | 2020-07-24 | RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck |
| NRG Oncology NRG-HN004 | Head And Neck Advanced | Open Active | 2019-03-20 | NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin |
| INST 1310 | Head And Neck Advanced | Open Active | 2015-02-25 | INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma |
| ECOG-ACRIN EA3161 | Head And Neck Advanced | Open Active | 2020-02-06 | ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA |
| SWOG S1712 | Hematology Chronic Leukemia | Open Active | 2019-02-21 | SWOG S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease |
| Alliance A041702 | Hematology Chronic Leukemia | Open Active | 2020-08-07 | Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) |
| UNM 1512 | Hematology Acute Leukemia | Open Active | 2018-05-23 | INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS |
| INST 0551C | Hematology Acute Leukemia | Open Active | 2016-05-02 | INST 0551C, Project 4 Dynamic Analysis of Signaling Networks in Leukemia |
| Alliance A041501 | Hematology Acute Leukemia | Open Active | 2020-04-03 | Alliance A041501: A PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN (A CONJUGATED ANTI-CD22 MONOCLONAL ANTIBODY) TO FRONTLINE THERAPY IN YOUNG ADULTS (AGES 18-39 YEARS) WITH NEWLY DIAGNOSED PRECURSOR B-CELL ALL |
| Pharm INCB 18424-MA-GD-301 | Hematology Stem Cell Transplant | Open Active | 2019-01-29 | Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant |
| ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2020-05-18 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
| SWOG S1803 | Hematology Myeloma | Open Active | 2019-11-14 | SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) |
| SWOG S1826 | Hematology Lymphoma Hodgkins | Open Active | 2020-05-08 | SWOG S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma |
| ECOG-ACRIN E4412 | Hematology Lymphoma Hodgkins | Open Active | 2020-03-13 | ECOG-ACRIN E4412: A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma |
| SWOG S1609 | Ill Defined | Open Active | 2019-12-10 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| INST 1306 | Ill Defined | Open Active | 2015-01-01 | INST 1306: Whole Genome Sequencing of Human Cancer Tissues |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-09 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| UNM 1709 | Ill Defined | Open Active | 2019-05-30 | INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER) |
| S1900B | Lung NSCLC Advanced | Open Active | 2020-09-11 | SWOG S1900B: A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2019-03-01 | ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| SWOG S1914 | Lung NSCLC Advanced | Open Active | 2020-08-27 | SWOG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC |
| SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-03-14 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
| Pharm M14-239 | Lung Other | Open Active | 2020-11-16 | AbbVie M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer |
| SWOG S1933 | Lung NSCLC Advanced | Open Active | 2020-11-25 | SWOG S1933: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status |
| NRG-LU005 | Lung SCLC Adjuvant | Open Active | 2020-02-05 | NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab |
| NRG Oncology NRG-CC003 | Lung SCLC Adjuvant | Open Active | 2020-08-24 | NRG Oncology NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer |
| EA2185 | Multiple Sites | Open Active | 2020-07-23 | EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs |
| SWOG S1929 | Lung SCLC Advanced | Open Active | 2021-01-13 | SWOG S1929: Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
| ECOG-ACRIN EA6141 | Skin Melanoma Advanced | Open Active | 2020-08-07 | ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2020-01-03 | ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2019-08-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| SWOG S1801 | Skin Melanoma Advanced | Open Active | 2020-04-03 | SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma |
| ECOG-ACRIN EAY131-Z1C | Solid Tumors Other | Open Active | 2020-05-07 | ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2019-09-16 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2019-11-15 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1K | Solid Tumors Other | Open Active | 2019-07-29 | ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations |
| Pharm BXQ-350.AA | Solid Tumors Other | Open Active | 2021-01-12 | Bexion BXQ-350.AA: Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients with Advanced Solid Tumors and Recurrent High-Grade Gliomas |
| ECOG-ACRIN EAY131-Z1L | Solid Tumors Other | Open Active | 2019-07-29 | ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations |
| Pharm SGNS40-001 | Solid Tumors Other | Open Active | 2019-12-18 | Seattle Genetics SGNS40-001: A Phase I, Open-label Dose Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies |
| Alliance A151804 | Supportive | Open Active | 2020-06-15 | Alliance A151804: Establishment of a National Biorepository to Advance Studies of Immune-related Adverse Events |
| DCP-001A | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001 | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| DCP-001C | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001B | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001D | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-002 | Supportive | Open Active | 2017-11-16 | NCI DCP-002: Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations |
| INST Johns Hopkins Hospital 1802 | Supportive | Open Active | 2019-09-20 | INST Johns Hopkins Hospital 1802: A Multi-Center Randomized Control Trial of Perioperative Palliative Care Surrounding Surgery for Patients and Their Family Members |
| ECOG-ACRIN E1Q11 | Supportive | Open Active | 2018-04-18 | ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship |
| WFU WF-1801 | Supportive | Open Active | 2019-09-27 | Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy |
| WFU WF 97115 | Supportive | Open Active | 2017-07-06 | WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer |
